Aksys to begin trial of first dialysis product:
This article was originally published in Clinica
Aksys has been given the go-ahead by the US FDA to begin trials of its personal haemodialysis system (PHD), the company's first product. The Lincolnshire, Illinois-based firm had filed its investigational device exemption in March, but the FDA had asked for validation of its software. Once the trial is complete, Aksys plans to submit a 510(k) clearance application before the third quarter of next year.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.